Published in Obesity and Diabetes Week, May 2nd, 2005
These injectable drug formulations will be used for pre-clinical and clinical studies for treatment of iron poisoning, iron overload, and diabetic complications. Production is scheduled to begin in the second quarter of 2005. Revenue from the agreement governing the BMF relationship is expected to contribute to modestly reducing Hemosol's burn rate in 2005.
"The key benefit to Hemosol from this agreement is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.